CytoMed Therapeutics Limited
GDTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $26,571 | $25,744 | $39,236 | $18,118 |
| - Cash | $2,245 | $2,125 | $3,639 | $3,867 |
| + Debt | $385 | $364 | $339 | $360 |
| Enterprise Value | $24,711 | $23,984 | $35,936 | $14,611 |
| Revenue | $106 | $100 | $52 | $109 |
| % Growth | 5.7% | 90.9% | -51.7% | – |
| Gross Profit | $98 | $93 | $92 | $97 |
| % Margin | 93.1% | 93.1% | 174.9% | 89.7% |
| EBITDA | -$804 | -$761 | -$482 | -$513 |
| % Margin | -760.9% | -760.9% | -920.4% | -472% |
| Net Income | -$882 | -$835 | -$1,077 | -$556 |
| % Margin | -834.7% | -834.7% | -2,055.1% | -511.6% |
| EPS Diluted | -0.075 | -0.071 | -0.093 | -0.048 |
| % Growth | -5.7% | 24.2% | -93.6% | – |
| Operating Cash Flow | -$629 | -$595 | -$569 | -$605 |
| Capital Expenditures | -$137 | -$129 | -$179 | -$191 |
| Free Cash Flow | -$766 | -$725 | -$748 | -$795 |